Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Siliq Probably Isn't The Light At The End Of Valeant's Tunnel

Executive Summary

Valeant is touting Siliq to lead new product growth, but the drug's significant safety concerns in a competitive psoriasis market likely will offset efficacy advantages it could offer.

You may also be interested in...



A Renewal Begins For Bausch (Née Valeant), But Challenges Ahead

The company reported a second quarter of organic sales growth, though revenues declined because of divestitures. Dermatology and Diversified Products segments continued to face challenges, and the company is working to respond to an FDA CRL for potential new dermatology product Duobrii.

Valeant Claims Progress, Asks Investors For Patience

The Canadian specialty pharma has exceeded its near-term debt-reduction goals, but are its plans for a return to growth grounded in reality? Market analysts recommend caution, but see some reason for optimism.

Valeant Sees Sunshine On Cloudy Day, But Dermatology Recovery Just Starting

The Bausch & Lomb and Salix units are gaining sales momentum, execs said, while debt-reduction efforts remain ahead of schedule. They offered no excuses for a declining dermatology franchise, however.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1129917

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel